Avery Dennison (averydennison.com) has introduced a line of new syringe labeling products to its pharmaceutical portfolio. The portfolio extension features safe, compliant label stock solutions, which meet manufacturers’ high standards for syringe and tight mandrel pharmaceutical applications.
“According to the IMS Institute for Healthcare Informatics, the global pharmaceutical segment is projected to grow to more than $1 trillion by 2018, with focused growth in the oncology, diabetes, pain and autoimmune therapy areas,” said David Collins, marketing director, specialty, Avery Dennison Label and Packaging Materials - North America.
High value drugs used to treat these ailments are commonly packaged in pre-filled syringes or vials and require labels that will remain securely in place during storage and use, and function according to the needs of the product.
“Choosing the right label solution can help customers avoid costly failures at the packaging line,” said Collins.
The new Avery Dennison syringe portfolio includes labeling solutions that offer low migration and high-performance adhesives on flexible paper and film facestocks. Products are sterilization-friendly and resistant to heat, steam and chemicals. Photoluminescent options are available to aid with missing label detection using ultraviolet light.
Adhesives used within the pharmaceutical industry must undergo comprehensive FDA testing to ensure they comply with toxicology requirements. If any adhesive changes are to occur, Avery Dennison notifies converters months in advance in order to make sure the new formulations are properly tested for compliance.
Avery Dennison has a team of technical solutions experts with vast industry knowledge ready to help customers find the right labeling solution for pharmaceutical applications.